Your browser doesn't support javascript.
loading
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
Sedegah, Martha; Porter, Chad; Goguet, Emilie; Ganeshan, Harini; Belmonte, Maria; Huang, Jun; Belmonte, Arnel; Inoue, Sandra; Acheampong, Neda; Malloy, Allison M W; Hollis-Perry, Monique; Jackson-Thompson, Belinda; Ramsey, Kathy F; Alcorta, Yolanda; Maiolatesi, Santina E; Wang, Gregory; Reyes, Anatolio E; Illinik, Luca; Sanchez-Edwards, Margaret; Burgess, Timothy H; Broder, Christopher C; Laing, Eric D; Pollett, Simon D; Villasante, Eileen; Mitre, Edward; Hollingdale, Michael R.
Afiliação
  • Sedegah M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Porter C; Translational Clinical Research Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Goguet E; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Ganeshan H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Belmonte M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Huang J; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Belmonte A; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Inoue S; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Acheampong N; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Malloy AMW; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Hollis-Perry M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Jackson-Thompson B; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Ramsey KF; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Alcorta Y; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Maiolatesi SE; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Wang G; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Reyes AE; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Illinik L; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Sanchez-Edwards M; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Burgess TH; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Broder CC; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Laing ED; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Pollett SD; Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Villasante E; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Mitre E; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Hollingdale MR; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
PLoS One ; 17(10): e0276241, 2022.
Article em En | MEDLINE | ID: mdl-36251675
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon gama / Interleucina-2 / COVID-19 Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferon gama / Interleucina-2 / COVID-19 Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos